Clinical Trials Browser

Phase 2 × Head and Neck Neoplasms × ibrutinib × Clear all

NCT03646461 2025-04-06

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms